ｄｄｄｄｄｄ

APASL Oncology 2024 Chiba“Genomics Meets Immunology:
Interdisciplinary Approach for Liver Cancer”

Scientific ProgramAPASL Oncology 2024 Chiba Scientific Program
Day 1: September 24 (Tuesday) 2024
Room 1 (The Club Fuji AB)
8:30-8:40 Opening Ceremony
Opening Remarks: Dr. Naoya Kato, President of APASL Oncology 2024 Chiba
8:40-10:20 Session 1: Current Insights into Molecular Pathways and Mechanisms

in Liver Cancer Development
Moderators: Dr. Lai Wei (China), Dr. Motoyuki Otsuka (Japan), Dr. Taro Yamashita (Japan)
Commentators: Dr. Yujin Hoshida (USA), Dr. Takahiro Kodama (Japan)

S1-1

Deciphering Liver Cancer: Molecular Pathways, Mechanisms, andIdentifying High-Risk Groups for Carcinogenesis and Recurrence
Dr. Yujin Hoshida (USA)S1-2

Leveraging Genomic Insights to Advance Liver Cancer Diagnosis andTreatment
Dr. Tatsuhiro Shibata (Japan)

S1-3

Liver Metabolism as a Driver of Hepatocarcinogenesis: Emerging
Concepts and Future Directions
Dr. Hayato Nakagawa (Japan)

S1-4

Unraveling the Complexity of Tumor Heterogeneity in HepatocellularCarcinoma: Intra-tumoral and Inter-tumoral Perspectives
Dr. Yosuke Hirotsu (Japan)

S1-5

Carcinogenesis and Its Evolution of Primary Liver Cancers from a
Pathological Perspective
Dr. Mina Komuta (Japan)

10:30-11:10 Special Lecture 1: Hepatitis Treatment: A Long-Term Investment inLiver Cancer Prevention and Survival
Moderators: Dr. Diana A. Payawal (Philippines), Dr. Norifumi Kawada (Japan)

SL1-1 Prevention of Primary Liver Cancer, China Perspective
Dr. Lai Wei (China)

SL1-2

Management of Portal Hypertension and its Complications in HCC:
A 2024 Update
Dr. Shiv K Sarin (India)

11:20-12:20 Session 2: APASL HCC Guideline and the Endeavor of A-HOCModerators: Dr. Shiv K Sarin (India) , Dr. Masao Omata (Japan)
Commentators: Dr. Oidov Baatarkhuu (Mongolia), Dr. Lai Wei (China)

S2-1

Landscape of Western HCC Guidelines
Dr. Arndt Vogel (Canada)

S2-2

The Latest APASL Clinical Practice Guideline on Systemic Therapy for
Hepatocellular Carcinoma
Dr. George Lau (China)

S2-3

A-HOC Start-up and Current State
Dr. Hitoshi Mochizuki (Japan)

12:30-13:30 Luncheon Seminar 1 (Gilead Sciences K.K.)
Moderator: Dr. Naoki Morimoto (Japan)“Current Topics on Viral Hepatitis”
LS1-1 Hepatitis C Treatment Progress Towards Elimination and Post-SVRIssues
Dr. Toshifumi Tada (Japan)

LS1-2 Innovative Strategies for Treating HBV-Related HCC: Insights fromBasic Research
Dr. Motoyuki Otsuka (Japan)
13:40-15:20 Session 3: Advances in Systemic Treatment Options for Liver Cancer
Moderators: Dr. Rino Gani (Indonesia), Dr. Masafumi Ikeda (Japan), Dr. Masayuki Kurosaki (Japan),Commentators: Dr. George Lau (China), Dr. Arndt Vogel (Canada)

S3-1

Current Systemic Therapy in Liver Cancer: Present Achievements andFuture Directions
Dr. Arndt Vogel (Canada)

S3-2

Advancing Systemic Therapy for Liver Cancer: Clinical Practice Insights
and Research Initiatives to Meet Unmet Needs
Dr. Changhoon Yoo (Korea)

S3-3

Harnessing the Power of Real-World Data to Address Clinical Challenges
in Systemic Therapy for Advanced Hepatocellular Carcinoma
Dr. Sadahisa Ogasawara (Japan)

S3-4

Pushing the Boundaries of Liver Cancer Treatment: Synergizing
Locoregional Therapy and Immunotherapy
Dr. Masatoshi Kudo (Japan)

S3-5

Personalized Approaches to Liver Cancer Management: Molecular andImmunological Landscape to Develop Novel Strategies
Dr. Shinji Tanaka (Japan)

15:30-16:30 Sponsored Seminar 1 (Eisai Co., Ltd.)
Moderator: Dr. Ryosuke Tateishi (Japan)

SS1Pushing the Envelope for Surgical Management of Advanced
Hepatocellular Carcinoma
Dr. Junichi Shindoh (Japan)

16:40-17:40 Plenary Session
Moderators: Dr. Jose Sollano (Philippines), Dr. Tatsuya Yamashita (Japan)
Commentators: Dr. Hayato Hikita (Japan), Dr. Kaoru Tsuchiya (Japan)

O-1 10041
Long-term Hepatocellular Carcinoma Occurrence Rate after Administration ofNucleos(t)ide Analogues in Patients with Persistent HBV Infection
Dr. Kazuhiro Murai (Japan)

O-2 10016
Spatial Omics Analysis of the Proximity of PD-L1(+) Tumor-AssociatedMacrophage and CD8T cell Interaction Promoting Hepatocellular Carcinoma
Progression
Dr. Takuto Nosaka (Japan)

O-3 10064
Comparative Pathological and Comprehensive Genomic Analysis forDifferential Diagnosis between IM and MC
Dr. Kenji Amemiya (Japan)

O-4 10118
Relationship between Anti-tumor Response and Immune-mediated Adverse
Events Requiring High-dose Corticosteroids in Unresectable Hepatocellular
Carcinoma Treated with Durvalumab plus Tremelimumab
Dr. Takanori Ito (Japan)

O-5 10154
Prognostic Factors after Carbon-ion Rradiotherapy: A Study Based on Multiinstitutional Registry Data
Dr. Kei Shibuya (Japan)

O-6 10163
Contour Prognostic Model: Effect of Diameter and Number of Hepatocellular
Carcinomas on Survival after Resection, Trans-Arterial Chemoembolization,and Ablation (The Liver Cancer Study Group of Japan)
Dr. Yoshikuni Kawaguchi (Japan)
17:50-18:50 Poster Session Day 1
At Room 2 “The Club Fuji C” , 1st Floor, Sheraton Grande Tokyo Bay Hotel
19:00-19:20 Awarding Ceremony of Day 1
At Room “Kegon”, 1st Floor, Sheraton Grande Tokyo Bay Hotel
19:20-20:30 Welcome Reception
At Room “Kegon”, 1st Floor, Sheraton Grande Tokyo Bay HotelDay 1: September 24 (Tuesday) 2024
Room 2 (The Club Fuji C)
12:30-13:30 Luncheon Seminar 2 (Chugai Pharmaceutical Co., Ltd.)
Moderator: Dr. Masayuki Kurosaki (Japan)

LS2-1 Remaining Clinical Questions and Unmet Needs in the Era ofImmunotherapy for Unresectable Hepatocellular Carcinoma
Dr. Takeshi Terashima (Japan)
LS2-2 Future Perspectives of Systemic Chemotherapy and Surgery in theTreatment of Hepatocellular Carcinoma
Dr. Shohei Komatsu (Japan)

15:30-16:30 Sponsored Seminar 2 (AbbVie GK)
Moderator: Dr. Tadashi Ikegami (Japan)

SS2 DAA Treatment for Chronic Hepatitis C and Future Challenges
Dr. Nobuharu Tamaki (Japan)

Day 2: September 25 (Wednesday) 2024
Room 1 (The Club Fuji AB)
7:30-8:30 Morning Seminar 1 (Incyte Biosciences Japan G.K.)
Moderator: Dr. Masayuki Otsuka (Japan)

MS1 New Treatment Strategy for Intrahepatic Cholangiocarcinoma
Dr. Makoto Ueno (Japan)
8:40-9:40 Session 4: From Mechanisms to Treatment: Targeting the Tumor

Microenvironment and Immune Landscape
Moderators: Dr. Tatsuya Kanto (Japan), Dr. Yasuhito Tanaka (Japan)Commentators: Dr. Carmen Wong (China)

S4-1

Tumor Microenvironment and Immune Response in Cancer
Dr. Yosuke Togashi (Japan)

S4-2

Advancements and Future Directions in the Study of the Immune
Landscape of Liver Cancer
Dr. Carmen Wong (China)

S4-3

Challenging in Biomarker Discovery: Targeting the Tumor
Microenvironment in Hepatocellular Carcinoma
Dr. Takahiro Kodama (Japan)

9:50-10:50 Sponsored Seminar 3 (Chugai Pharmaceutical Co., Ltd.)
Moderator: Dr. Masafumi Ikeda (Japan)

SS3

Real-World Clinical Impact of Atezolizumab plus Bevacizumab inPatients with Advanced Hepatocellular Carcinoma - A 4-Year
Experience
Dr. Teiji Kuzuya (Japan)

11:00-11:40 Special Lecture 2: Hepatology in Asia: Navigating the Landscape ofLiver Diseases
Moderators: Dr. Kadir Dokmeci (Turkey), Dr. Osamu Yokosuka (Japan)

SL2-1 HCC Etiology, Incidence, Diagnosis, Management and Survival in
Mongolia, Update of A-HOC Studies
Dr. Jazag Amarsanaa (Mongolia)

SL2-2Hepatology in Asia: Navigating the Landscape of Liver Diseases (HCC)
Dr. Masao Omata (Japan)

11:50-12:50 Luncheon Seminar 3 (AbbVie GK)
Moderator: Dr. Yoshiyuki Ueno (Japan)“Topics on Treatment of Liver Diseases, HCV Infection and HCC”
LS3-1 Multidisciplinary Treatment Including Ultra-FP, iCIs and Ablation
Therapy should be Considered to Control HCC
Dr. Yasuteru Kondo (Japan)

LS3-2 Pharmacokinetics of Direct-Acting Antiviral Therapy for Hepatitis C
Virus Infection
Dr. Hironao Okubo (Japan)
13:00-15:00 Session 5: Integrated Therapeutic Strategies for Liver Cancer: A

Multidisciplinary Perspective
Moderators: Dr. Tawesak Tanwandee (Thailand), Dr. Kiyoshi Hasegawa (Japan),
Dr. Shuntaro Obi (Japan), Dr. Naoya Sakamoto (Japan)
Commentators: Dr. Stephen Lam Chan (China), Dr. Yi-Hsiang Huang (Taiwan)

S5-1

From Early to Advanced Stages: Navigating Hepatocellular Carcinoma
Treatment with Systemic Therapy
Dr. Stephen Lam Chan (China)

S5-2

Multifaceted Strategies for Hepatocellular Carcinoma in Asia: Improving
Patient Outcomes with Optimal Treatment Modalities
Dr. Yi-Hsiang Huang (Taiwan)

S5-3

Surgical Resections in Hepatocellular Carcinoma: Evolving in Tandemwith Advancements in Systemic Therapy
Dr. Shinji Itoh (Japan)

S5-4

The Role of Percutaneous Ablation in the Treatment of Liver Cancer: A
Response to Shifting Disease Patterns and Treatment Landscapes
Dr. Ryosuke Tateishi (Japan)

S5-5

The Evolving Landscape of Transarterial Therapy for Liver Cancer:
Current Practices and Emerging Trends
Dr. Toshihiro Tanaka (Japan)

S5-6

Radiation Therapy in Liver Cancer: Insights into Current Impact andFuture Prospects
Dr. Masaru Wakatsuki (Japan)

15:10-16:10 Sponsored Seminar 5 (FUJIFILM Wako Pure Chemical Corporation)
Moderator: Dr. Masao Omata (Japan)

SS5

AFP-L3: An Old and New Marker Specific for the Management of HCC
Dr. Hidenori Toyoda (Japan)

16:20-17:20 Poster Session Day 2At Room 2 “The Club Fuji C” , 1st Floor, Sheraton Grande Tokyo Bay Hotel
17:30-17:50 Awarding Ceremony of Day 2
17:50-17:55 Closing Ceremony
Closing Remarks: Dr. Naoya Kato, President of APASL Oncology 2024 Chiba

Day 2: September 25 (Wednesday) 2024
Room 2 (The Club Fuji C)
7:30-8:30 Morning Seminar 2 (Miyarisan Pharmaceutical Co., Ltd.)
Moderator: Dr. Hitoshi Yoshiji (Japan)

MS2 Gut Microbiota in Host Health and Diseases Including Gastrointestinal
Cancers
Dr. Hiroshi Ohno (Japan)
9:50-10:50 Sponsored Seminar 4 (Gilead K.K.)
Moderator: Dr. Kazumoto Murata (Japan)

SS4Prediction and Prevention of Hepatocellular Carcinoma in Chronic
Liver Diseases
Dr. Taro Yamashita (Japan)

11:50-12:50 Luncheon Seminar 4 (Eisai Co., Ltd.)
Moderator: Dr. Masatoshi Kudo (Japan)“Treatment Strategy for Hepatocellular Carcinoma Focused on Tumor
Microenvironment”

LS4-1 Hepatocellular Carcinoma Treatment in the Era of Combined
Immunotherapy -Future Role of Lenvatinib in Light of the Tumor
Immune MicroenvironmentDr. Naoto Fujiwara (Japan)

LS4-2 Lenvatinib-based Treatment Strategy for Unresectable HepatocellularCarcinomaDr. Issei Saeki (Japan)
16:20-17:20 Poster Session Day 2